Prevalence of Fosfomycin Resistance Among Enterobacterales Isolates in A Tertiary Care Hospital from Turkey.

4区数学 Q4 Mathematics

Lecture Notes in Mathematics Pub Date : 2022-12-21 eCollection Date: 2022-12-01 DOI:10.36519/idcm.2022.163

Yeliz Tanrıverdi-Çaycı, Doğa Beliz Güne, Mustafa Ertokatlı, Kübra Hacıeminoğlu-Ülker, Asuman Birinci

{"title":"Prevalence of Fosfomycin Resistance Among Enterobacterales Isolates in A Tertiary Care Hospital from Turkey.","authors":"Yeliz Tanrıverdi-Çaycı, Doğa Beliz Güne, Mustafa Ertokatlı, Kübra Hacıeminoğlu-Ülker, Asuman Birinci","doi":"10.36519/idcm.2022.163","DOIUrl":null,"url":null,"abstract":"Objective: Urinary tract infections are one of the most common causes of morbidity around the world. Fosfomycin is a specific broad-spectrum antibiotic used to treat these infections. However, in recent years, many studies have reported increased fosfomycin resistance in Enterobacterales isolates. Therefore, this study aimed to evaluate the distribution of pathogens isolated from urine samples and find the fosfomycin resistance rates over nine years (2012-2020).Materials and methods: A total of 18,884 uropathogenic Enterobacterales isolates were included in the study between 2012 and 2020. The isolates were identified by VITEK® 2 Compact (bioMérieux, Marcy l'Etoile, France), and the antimicrobial susceptibilities of the isolates were also evaluated using the VITEK® MS automated system (bioMérieux, Marcy l'Etoile, France).Results: Escherichia coli (64.04%) was the most common bacteria among Enterobacterales. Fosfomycin resistance rates were 1.98%, 21.64%, and 10.36% in E. coli, Klebsiella pneumoniae, and all bacteria, respectively. The 34.97% of isolates were extended-spectrum β-lactamase (ESBL)-producing Enterobacterales, and the fosfomycin resistance rate was 13.08% in these isolates. In addition, fosfomycin resistance rates were found as 3.06% and 23.84% in ESBL-producing E. coli and ESBL-producing K. pneumoniae, respectively.Conclusion: Fosfomycin seems a good option for effectively treating UTIs caused by E. coli. On the other hand, we found that fosfomycin resistance tends to increase over the years. Therefore, we recommend further studies to evaluate fosfomycin resistance.","PeriodicalId":54743,"journal":{"name":"Lecture Notes in Mathematics","volume":"1139 1","pages":"252-257"},"PeriodicalIF":0.0000,"publicationDate":"2022-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10985827/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lecture Notes in Mathematics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36519/idcm.2022.163","RegionNum":4,"RegionCategory":"数学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/12/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"Mathematics","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Urinary tract infections are one of the most common causes of morbidity around the world. Fosfomycin is a specific broad-spectrum antibiotic used to treat these infections. However, in recent years, many studies have reported increased fosfomycin resistance in Enterobacterales isolates. Therefore, this study aimed to evaluate the distribution of pathogens isolated from urine samples and find the fosfomycin resistance rates over nine years (2012-2020).

Materials and methods: A total of 18,884 uropathogenic Enterobacterales isolates were included in the study between 2012 and 2020. The isolates were identified by VITEK^® 2 Compact (bioMérieux, Marcy l'Etoile, France), and the antimicrobial susceptibilities of the isolates were also evaluated using the VITEK^® MS automated system (bioMérieux, Marcy l'Etoile, France).

Results: Escherichia coli (64.04%) was the most common bacteria among Enterobacterales. Fosfomycin resistance rates were 1.98%, 21.64%, and 10.36% in E. coli, Klebsiella pneumoniae, and all bacteria, respectively. The 34.97% of isolates were extended-spectrum β-lactamase (ESBL)-producing Enterobacterales, and the fosfomycin resistance rate was 13.08% in these isolates. In addition, fosfomycin resistance rates were found as 3.06% and 23.84% in ESBL-producing E. coli and ESBL-producing K. pneumoniae, respectively.

Conclusion: Fosfomycin seems a good option for effectively treating UTIs caused by E. coli. On the other hand, we found that fosfomycin resistance tends to increase over the years. Therefore, we recommend further studies to evaluate fosfomycin resistance.

查看原文本刊更多论文

土耳其一家三级医院肠杆菌属隔离菌对磷霉素耐药性的流行情况

目的：尿路感染是全球最常见的发病原因之一。磷霉素是一种用于治疗此类感染的特异性广谱抗生素。然而，近年来许多研究报告称，肠杆菌属分离物对磷霉素的耐药性有所增加。因此，本研究旨在评估从尿液样本中分离出的病原体的分布情况，并发现九年内（2012-2020 年）的磷霉素耐药率：研究共纳入了 2012 年至 2020 年间分离的 18884 株尿路致病性肠杆菌。这些分离物通过 VITEK® 2 Compact（生物梅里埃，法国马西埃托尔）进行鉴定，并使用 VITEK® MS 自动系统（生物梅里埃，法国马西埃托尔）对分离物的抗菌药敏感性进行评估：结果：肠杆菌科细菌中最常见的是大肠埃希菌（64.04%）。大肠埃希菌、肺炎克雷伯菌和所有细菌对磷霉素的耐药率分别为 1.98%、21.64% 和 10.36%。34.97%的分离菌株为产广谱β-内酰胺酶（ESBL）的肠杆菌科细菌，这些分离菌株对磷霉素的耐药率为13.08%。此外，产 ESBL 的大肠杆菌和产 ESBL 的肺炎双球菌对磷霉素的耐药率分别为 3.06% 和 23.84%：结论：磷霉素似乎是有效治疗由大肠杆菌引起的UTI的一个不错选择。结论：磷霉素似乎是有效治疗由大肠杆菌引起的UTI的不错选择，但我们发现磷霉素的耐药性有逐年增加的趋势。因此，我们建议进一步开展研究，评估磷霉素的耐药性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Lecture Notes in Mathematics Mathematics-Algebra and Number Theory

CiteScore

0.50

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： This series reports on new developments in all areas of mathematics and their applications - quickly, informally and at a high level. Mathematical texts analysing new developments in modelling and numerical simulation are welcome. The type of material considered for publication includes: 1. Research monographs 2. Lectures on a new field or presentations of a new angle in a classical field 3. Summer schools and intensive courses on topics of current research. Texts which are out of print but still in demand may also be considered if they fall within these categories. The timeliness of a manuscript is sometimes more important than its form, which may be preliminary or tentative.